|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03347 TIGERMED
Nominal 
41.000 -0.920 (-2.195%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 3,707,560 | 14.063% | 6,832,801 | 6,603,120 | 7,384,039 | 7,085,471 |
| Cost of Sales | (2,687,044) | -- | -- | -- | -- | (4,300,027) |
| Gross Profit | 1,020,516 | -- | -- | -- | -- | 2,785,444 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (444,201) | 273.422% | 5,213 | (535,709) | 284,672 | (24,575) | |
| Profit / (Loss) on Disposal | (18,083) | -- | 3,651 | 3,563 | (188) | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 21,662 | -86.981% | 198,507 | 31,271 | 105,183 | 39,763 | |
| Profit / (Loss) before Taxation | (80,215) | -- | 1,003,215 | 664,462 | 2,488,533 | 2,594,912 | |
| Taxation | (105,256) | 31.799% | (198,159) | (216,630) | (338,606) | (313,652) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (227,688) | -- | 82,834 | (42,688) | (125,077) | (265,174) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (413,160) | -- | 887,890 | 405,143 | 2,024,850 | 2,016,086 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 42,285 | -33.181% | 99,902 | 38,067 | (108,324) | (145,249) |
| Depreciation & Amortisation | 181,171 | -1.797% | 369,476 | 364,036 | 339,023 | 284,844 |
| Directors' Emoluments | -- | -- | 8,735 | 9,192 | 8,929 | 7,871 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | -48.000 | -- | 104.000 | 47.000 | 234.000 | 233.000 |
| DPS (cts) | 0.000 | -- | 12.600 | 30.000 | 56.800 | 55.000 |
| Dividend Payout Ratio (%) | -- | -- | 12.115% | 63.830% | 24.274% | 23.605% |
| Cash flow per share ($) | -- | -- | 1.306 | 1.271 | 1.330 | 1.311 |
| NBV per share ($) | 22.621 | -- | 24.510 | 24.000 | 24.102 | 22.499 |
| Remarks: | Real time quote last updated: 11/09/2026 11:43 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -413,160 |
| %Change | -- |
| EPS / (LPS) | RMB -0.480 |
| NBV Per Share (¥) | RMB 22.621 |